1981 年 30 巻 3 号 p. 141-154
Growth kinetic curves of various human genitourinary cancer cell lines following treatment with an anticancer drug were determined to find a reliable index of cell damage. They showed a triphasic growth pattern consisting of growth inhibition phase, exponential growth phase (regrowth phase) and stationary phase. The percent survival at the turning point from growth inhibition phase to regrowth phase was considered to be a reliable cell damage index indicating to what extent the proliferative capacity of a cell population was impaired by treatment with the drug.
Dose-response curves determined by this assay procedure of cell damage (regrowth assay method) clarified the cell reduction kinetics of cis-plati-num (II) diammine dichloride and bleomycin that would provide a rational basis for the mode of their administration in clinical use. They also disclosed the differential drug sensitivities among the cell lines derived from cancers of the different organs represented by HeLa S3, KU 1 and KU 2 and among those from cancers of the same histological type represented by KU 2, NRC 12 and OUR 10 from renal cell carcinoma and KU 1, MGH-U1 and T 24 from transitional cell carcinoma of the bladder. These results suggested that, as the increasing number of human cancer cell lines is established, correlation be-tween drug sensitivity and morphological and functional properties of cancer can be investigated in vitro and the results might provide a rational basis for drug selection.
It was concluded that the regrowth assay method to determine drug-induced cell damage in vitro not only has a wide applicability but also is reli-able enough to clarify the cell reduction kinetics of anticancer drugs and the differential drug sensitivities among various genitourinary cancer cell lines.
